MIRA - Ketamine Biotech Company with massive growth potential!
Zaktualizowano
Mira Pharmaceuticals Inc is a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a broad range of neurologic and neuropsychiatric disorders. The company's novel oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia.
Float 9.96M
Recent News from 29/10/2024:
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
"MIRA Pharmaceuticals (MIRA, Financial) shares soared by 40% after the company achieved a significant breakthrough in chemotherapy pain management with its new drug, Ketamir-2. According to recent studies, Ketamir-2 is proven to be 2% more effective than existing FDA-approved medications, specifically Gabapentin and Pregabalin, in alleviating chemotherapy-induced neuropathic pain. Preclinical studies have highlighted Ketamir-2's superior performance, demonstrating a 60% higher efficacy compared to Gabapentin and a remarkable 112% improvement over Pregabalin in various neuropathic models.
Chronic neuropathic pain, in particular, which develops from nerve damage caused by chemotherapy or injury, has only Gabapentin and Pregabalin available as effective therapy now. Alas, such medications are not without their drawbacks, which include dizziness, impairment of cognitive function, and dependency inclusion. The market for both Gabapentin and Pregabalin is going to have healthy growth rates in the forecast period of 2020 to 2033, with Gabapentin reaching $4.95 Billion.
Ketamir-2's superior performance in preclinical studies is coupled with fewer adverse side effects, presenting a potentially safer option for long-term pain management. This non-opioid alternative addresses the urgent need for treatments that minimize the risk of addiction. With its promising results, Ketamir-2 may soon qualify for FDA breakthrough therapy designation or fast-track status, especially for rare cancer-related neuropathic pains.
In addition to ketamine-2, MIRA Pharmaceuticals is also active in developing MIRA-55, an oral agent with a similar mechanism as ketamine-2 used in the treatment of anxiety and cognitive symptoms in early dementia. With Ketamir-2 moving towards clinical trial and possibly receiving expedited approval by the FDA, it becomes a true light at the end of the tunnel for those suffering from chronic and severe pain."
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$2.60 - 2.65
Resistance Points:
$3.30
$3.75
$4.15
$5.15
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Trading Strategy:
I see a cup and handle formation.
Take Profit (TP): Set a target at $6.33. If FDA approval is granted, this stock has the potential to surge significantly, with a possible price target of $15.00 or even higher.
Stop Loss (SL): Set at under $1.3 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
Float 9.96M
Recent News from 29/10/2024:
MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
"MIRA Pharmaceuticals (MIRA, Financial) shares soared by 40% after the company achieved a significant breakthrough in chemotherapy pain management with its new drug, Ketamir-2. According to recent studies, Ketamir-2 is proven to be 2% more effective than existing FDA-approved medications, specifically Gabapentin and Pregabalin, in alleviating chemotherapy-induced neuropathic pain. Preclinical studies have highlighted Ketamir-2's superior performance, demonstrating a 60% higher efficacy compared to Gabapentin and a remarkable 112% improvement over Pregabalin in various neuropathic models.
Chronic neuropathic pain, in particular, which develops from nerve damage caused by chemotherapy or injury, has only Gabapentin and Pregabalin available as effective therapy now. Alas, such medications are not without their drawbacks, which include dizziness, impairment of cognitive function, and dependency inclusion. The market for both Gabapentin and Pregabalin is going to have healthy growth rates in the forecast period of 2020 to 2033, with Gabapentin reaching $4.95 Billion.
Ketamir-2's superior performance in preclinical studies is coupled with fewer adverse side effects, presenting a potentially safer option for long-term pain management. This non-opioid alternative addresses the urgent need for treatments that minimize the risk of addiction. With its promising results, Ketamir-2 may soon qualify for FDA breakthrough therapy designation or fast-track status, especially for rare cancer-related neuropathic pains.
In addition to ketamine-2, MIRA Pharmaceuticals is also active in developing MIRA-55, an oral agent with a similar mechanism as ketamine-2 used in the treatment of anxiety and cognitive symptoms in early dementia. With Ketamir-2 moving towards clinical trial and possibly receiving expedited approval by the FDA, it becomes a true light at the end of the tunnel for those suffering from chronic and severe pain."
Overall Market Sentiment:
It’s always crucial to consider overall market sentiment when making trading decisions.
Breakout Zone:
$2.60 - 2.65
Resistance Points:
$3.30
$3.75
$4.15
$5.15
Surpassing these levels could signal a positive trend. Consider taking profits at these stages to realize gains.
Trading Strategy:
I see a cup and handle formation.
Take Profit (TP): Set a target at $6.33. If FDA approval is granted, this stock has the potential to surge significantly, with a possible price target of $15.00 or even higher.
Stop Loss (SL): Set at under $1.3 to mitigate potential losses.
Chart Analysis:
Please refer to the attached chart for detailed analysis of price trends and movements.
Trading Advisory:
Exercise caution and consider market conditions and your own risk tolerance when trading. It's advisable to conduct comprehensive research or consult with a financial advisor before engaging in trading activities.
Disclaimer: This content is for informational purposes only and should not be considered financial advice.
Transakcja zakończona: osiągnięto poziom stop
SL hit
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
Wyłączenie odpowiedzialności
Informacje i publikacje przygotowane przez TradingView lub jego użytkowników, prezentowane na tej stronie, nie stanowią rekomendacji ani porad handlowych, inwestycyjnych i finansowych i nie powinny być w ten sposób traktowane ani wykorzystywane. Więcej informacji na ten temat znajdziesz w naszym Regulaminie.